HIFEM and Radiofrequency for Muscular System Function Improvement

N/AActive Not RecruitingNCT06703749

BTL Industries Ltd.33 enrolled

Overview

The goal of this clinical trial is to investigate the effect of the BTL-899M device on muscular system function in adult subjects seeking treatment for improving their muscular system function in the lower extremities. The main question it aims to answer is: Whether the BTL-899M device is effective for muscular system function improvement 3 months posttreatment compared to the sham group, based on the dynamometer measurement. Researchers will compare a sham group to see if the device is effective. Participants will complete four treatment visits and two follow-up visits. Their strength will be recorded via a dynamometer.

This study will evaluate the clinical efficacy and safety of the BTL-899M device for changes in muscular system function through muscle strength measurement by hand-held dynamometer. The study is a prospective, multi-center, open-label, single-arm study. The subjects will be enrolled and assigned to two groups - active and sham in a 3:1 ratio. All patients will be required to complete four (4) treatment visits receiving the treatment with the study device and two follow-up visits at 1 month and 3 months. The sham group will be treated with 5% of both energies only. The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. The device will induce visible muscle contractions along with heating by radiofrequency (RF). Each therapy session will last 30 minutes. At baseline, after the last treatment, and all follow-up visits, the strength measurement of the treated area will be performed by hand-held dynamometer in all subjects. At the last therapy visit, the patients will receive the Subject Satisfaction Questionnaire and Therapy Comfort Questionnaire to fill in. Subject satisfaction questionnaire will be given to the subjects at all follow-up visits. Safety measures will include documentation of adverse events (AE), which will be assessed after each procedure and at all follow-up visits. During the post-procedure visits (at 1-month and 3-month follow-up visits), all subjects will receive the Lifestyle Change Questionnaire to fill in.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

Interventions

Treatment with BTL-899MDEVICE

The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The starting intensity of the radiofrequency energy will be set to 100%. The intensities of both energies will be adjusted according to the patient's feedback.

Treatment with BTL-899M with intensities below therapeutic thresholdDEVICE

The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The intensities of both energies will be set below the therapeutic threshold.

Eligibility

Sex: ALLMin age: 22 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 22 years and older * Voluntarily signed an informed consent form * BMI ≤ 35 kg/m2 * Women of child-bearing potential are required to use birth control measures during the whole duration of the study * Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime and the study procedure for improvement of the musculoskeletal system * Subjects willing and able to maintain their regular (pre-procedure) diet, exercise and therapy regimen without affecting significant change in either direction during study participation Exclusion Criteria: * Electronic implants (such as cardiac pacemakers, defibrillators, and neurostimulators) * Metal implants * Drug pumps * Malignant tumor * Pulmonary insufficiency * Application over muscles in the acute phase of injury * Cardiovascular diseases * Disturbance of temperature or pain perception * Hemorrhagic conditions, blood coagulation disorders or anticoagulation therapy * Septic conditions and empyema * Acute inflammations * Systemic or local infection such as osteomyelitis and tuberculosis * Contagious skin disease * Elevated body temperature * Pregnancy, postpartum period, and nursing * Graves' disease

Outcomes

Primary Outcomes

% change from baseline in the muscle strength for the active group vs. sham group at 3 months.

The evaluation of the percentual (%) change in muscle strength in the active group by evaluation of dynamometer score 3 months posttreatment compared to the sham group

Time frame: baseline and 3 months

Secondary Outcomes

Subject satisfaction as assessed by Subject Satisfaction Questionnaire at 3 months

Subject Satisfaction evaluation based on the Subject Satisfaction Questionnaire administered 3 months posttreatment

Time frame: from the first therapy to the 3 months after the last treatment session

Comfort as assessed by Therapy Comfort Questionnaire after the final treatment

Therapy comfort evaluation through the Therapy Comfort Questionnaire administered after the final treatment

Time frame: from the first to the last treatment session, assessed up to 40 days

Incidence of Treatment-related Adverse Events

Assessment of safety throughout the course of the study by evaluting the the side effects and AE occurrence throughout the course of the study

Time frame: from the first therapy to the end of subject's participation, assessed up to 5 months